Results 1 to 10 of about 32,649 (166)
Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies [PDF]
Frontiers in ImmunologyWith the expanding identification of target antigens in primary membranous nephropathy (PMN), treatment is shifting from empirical immunosuppression toward mechanism-based precision immunotherapy.
Jingjie Gao +9 more
doaj +2 more sources
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting [PDF]
Molecular OncologyDevelopment of chimeric antigen receptor T‐cell therapy has revolutionized the treatment of B‐cell malignancies, although challenges such as antigen escape and tumor heterogeneity often decrease treatment success. Modular CARs targeting multiple antigens
Pablo Gonzalez‐Garcia +9 more
doaj +2 more sources
Neurology International, 2022 Anti-CD20 therapies decrease the humoral response to SARS-CoV-2 immunization. We aimed to determine the extent of the humoral response to SARS-CoV-2 antigens in correlation with peripheral B-cell dynamics among patients with central nervous system ...
Julia Feige +11 more
doaj +1 more source
Immuno-biosensor for Detection of CD20-Positive Cells Using Surface Plasmon Resonance [PDF]
Advanced Pharmaceutical Bulletin, 2017 Purpose: Surface plasmon resonance (SPR) sensing confers a real-time assessment of molecular interactions between biomolecules and their ligands. This approach is highly sensitive and reproducible and could be employed to confirm the successful binding ...
Dariush Shanehbandi +6 more
doaj +1 more source
Frontiers in Immunology, 2023 The activating receptor natural killer group 2, member D (NKG2D) represents an attractive target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by regulating the activity of cytotoxic lymphocytes.
Sebastian Lutz +19 more
doaj +1 more source
Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases [PDF]
Archive of Oncology, 2009 Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all ...
Pejčić Ivica, Vrbić Svetislav
doaj +1 more source
Journal of Veterinary Medical Science, 2021 Chimeric antigen receptor (CAR) CAR-T cell therapy targeting CD20 can be a novel adoptive cell therapy for canine patients with B-cell malignancy. After injection of the CAR-T cells in vivo, monitoring circulating CAR-T cells is essential to prove in vivo persistence of CAR-T cells. In this study, we developed a novel monoclonal antibody against canine
SAKAI, Osamu +4 more
openaire +3 more sources
Diagnostics, 2020 Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common entity of mature T-cell neoplasms. PTCL-NOS generally has an aggressive behavior and is often refractory to standard therapy.
Alessandro Mangogna +5 more
doaj +1 more source
Monoclonal antibody-based therapies for Waldenström's macroglobulinemia
Leukemia Research Reports, 2022 Monoclonal antibodies have established an important role in the treatment armamentarium of hematological malignancies, including Waldenström's macroglobulinemia.
Despina Fotiou +2 more
doaj +1 more source
Hematology/Oncology and Stem Cell Therapy, 2013 BACKGROUND AND OBJECTIVES: The role of bone marrow-mesenchymal stem cells (BM-MSC) in leukae-mic cell control is controversial. The purpose of this work was to evaluate BM-MSC role regarding the viability, proliferation and immunophenotype of normal B ...
Viviana M Rodríguez-Pardo +7 more
doaj +1 more source